SG11201609442YA - Improved polyethyleneimine polyethyleneglycol vectors - Google Patents

Improved polyethyleneimine polyethyleneglycol vectors

Info

Publication number
SG11201609442YA
SG11201609442YA SG11201609442YA SG11201609442YA SG11201609442YA SG 11201609442Y A SG11201609442Y A SG 11201609442YA SG 11201609442Y A SG11201609442Y A SG 11201609442YA SG 11201609442Y A SG11201609442Y A SG 11201609442YA SG 11201609442Y A SG11201609442Y A SG 11201609442YA
Authority
SG
Singapore
Prior art keywords
vectors
improved
polyethyleneglycol
polyethyleneimine
polyethyleneimine polyethyleneglycol
Prior art date
Application number
SG11201609442YA
Inventor
Alex Levitzki
Salim Joubran
Alexei Shir
Maya Zigler
Alaa Talhami
Yael Langut
Original Assignee
Alex Levitzki Man And Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alex Levitzki Man And Holdings Ltd filed Critical Alex Levitzki Man And Holdings Ltd
Publication of SG11201609442YA publication Critical patent/SG11201609442YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
SG11201609442YA 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors SG11201609442YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993110P 2014-05-14 2014-05-14
PCT/IL2015/050514 WO2015173824A1 (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Publications (1)

Publication Number Publication Date
SG11201609442YA true SG11201609442YA (en) 2016-12-29

Family

ID=54479412

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201911695SA SG10201911695SA (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors
SG11201609442YA SG11201609442YA (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201911695SA SG10201911695SA (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Country Status (17)

Country Link
US (4) US10278991B2 (en)
EP (1) EP3142673A4 (en)
JP (3) JP6753843B2 (en)
KR (2) KR102472590B1 (en)
CN (3) CN116966311A (en)
AU (2) AU2015260725B2 (en)
BR (1) BR112016026581A2 (en)
CA (1) CA2949017A1 (en)
IL (2) IL287206B2 (en)
MA (1) MA39970A (en)
MX (2) MX2016014881A (en)
NZ (1) NZ727092A (en)
PH (1) PH12016502258A1 (en)
RU (1) RU2771104C2 (en)
SG (2) SG10201911695SA (en)
WO (1) WO2015173824A1 (en)
ZA (1) ZA201608042B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102472590B1 (en) * 2014-05-14 2022-11-30 타르그이뮨 테라퓨틱스 아게 Improved polyethyleneimine polyethyleneglycol vectors
DE202016008594U1 (en) 2015-11-17 2018-08-23 Bioncotech Therapeutics S.L A novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
KR102372857B1 (en) * 2016-03-07 2022-03-11 한미약품 주식회사 Polyethylene glycol derivatives and use thereof
JP7096249B2 (en) 2016-09-04 2022-07-05 ターグイミューン セラピューティクス アーゲー Chimeric protein for targeting dsRNA
PL3448363T3 (en) 2017-05-17 2022-09-26 Highlight Therapeutics, S.L. Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN111164093A (en) * 2017-09-27 2020-05-15 塔尔格免疫治疗有限公司 Castration resistant prostate cancer
US20200407453A1 (en) * 2018-03-08 2020-12-31 Targimmune Therapeutics Ag A recombinant protein comprising a double stranded rna binding domain
CN109893657B (en) * 2019-02-28 2022-04-29 中国人民解放军军事科学院军事医学研究院 Gene delivery carrier, drug compound, anti-pulmonary fibrosis drug and application
US20220175814A1 (en) * 2019-04-03 2022-06-09 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
WO2020263782A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Methods and compositions for modifying nucleic acids and for killing cells
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
CA3192963A1 (en) 2020-10-08 2022-04-14 Esteban Pombo-Villar Immunotherapy for the treatment of cancer
WO2023079142A2 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
US20240091348A1 (en) * 2022-09-20 2024-03-21 Highlight Therapeutics, S.L. Novel compositions based on polyinosinic-polycytidylic acid

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3222461B2 (en) 1990-05-18 2001-10-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New protein-polycation conjugate
DE4104186A1 (en) 1991-02-12 1992-08-13 Genentech Inc NEW COMPLEXES INCLUDING ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE19726186A1 (en) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
ATE473748T1 (en) 1998-05-25 2010-07-15 Nippon Shinyaku Co Ltd METHOD FOR PRODUCING A COMPOSITION COMPOSITION CONTAINING NUCLEIC ACID
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20040043030A1 (en) 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
GB0119346D0 (en) 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
KR20030043780A (en) 2001-11-28 2003-06-02 주식회사 바이오폴리메드 Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
AU2002236324A1 (en) 2002-02-28 2003-09-09 Jong Sang Park Cationic highly branched polyaminoester
CN1720257A (en) 2002-08-06 2006-01-11 因特拉迪格姆公司 Methods of down regulating target gene expression in vivo by introduction of interfering RNA
US7927792B2 (en) * 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US8324365B2 (en) 2003-04-03 2012-12-04 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050118718A1 (en) 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
US20050277575A1 (en) 2004-03-24 2005-12-15 Alexandre Semov Therapeutic compositions and methods for treating diseases that involve angiogenesis
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101287500A (en) * 2005-08-19 2008-10-15 恩多塞特公司 Multi-drug ligand conjugates
WO2007133812A2 (en) 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
CA2637931A1 (en) 2006-01-23 2007-07-26 Abbott Laboratories Chemically modified polycation polymer for sirna delivery
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
ES2776100T3 (en) 2006-03-31 2020-07-29 Massachusetts Inst Technology System for targeted delivery of therapeutic agents
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
SI2187965T1 (en) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Psma binding ligand-linker conjugates and methods for using
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
SI2644594T1 (en) 2007-09-28 2017-10-30 Pfizer Inc. Cancer Cell Targeting Using Nanoparticles
CA2917512A1 (en) 2007-10-12 2009-04-23 Massachusetts Institute Of Technology Vaccine nanotechnology
US20110027172A1 (en) 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation
WO2009086640A1 (en) 2008-01-10 2009-07-16 Nventa Biopharmaceuticals Corporation Adjuvant compositions comprising poly-ic and a cationic polymer
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
EP2113257A1 (en) 2008-04-30 2009-11-04 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer
EP2123304A1 (en) 2008-05-23 2009-11-25 Freie Universität Berlin Compounds suited as nanocarriers for active agents and their use
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
SI2285350T1 (en) 2008-06-16 2018-03-30 Pfizer Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
SI3098239T1 (en) * 2008-12-22 2020-03-31 Targimmune Therapeutics Ag Egfr-homing double-stranded rna vector for systemic cancer treatment
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
US20100266642A1 (en) 2009-02-20 2010-10-21 Bind Biosciences, Inc. Modified cells for targeted cell trafficking and uses thereof
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
ES2368963B1 (en) 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii PROCEDURE FOR IDENTIFICATION OF THERAPEUTIC AGENTS AGAINST MELANOMA AND USE OF IDENTIFIED AGENT.
CN101638484A (en) * 2009-08-24 2010-02-03 中国科学院长春应用化学研究所 Polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, preparation method thereof and application thereof
CN102665758A (en) 2009-12-09 2012-09-12 Ibc药品公司 Dock-and-lock (DNL) Complexes For Delivery of Interference RNA
JP5965844B2 (en) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド Therapeutic polymer nanoparticle compositions having high glass transition temperature or high molecular weight copolymers
JP6175237B2 (en) 2009-12-15 2017-08-02 ファイザー・インク Therapeutic polymer nanoparticles containing corticosteroids and methods of making and using the same
EA201290498A1 (en) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. THERAPEUTIC POLYMER NANOPARTICLES, INCLUDING EPOTILON, AND METHODS FOR THEIR PREPARATION AND APPLICATION
CN102869774B (en) 2010-02-24 2018-02-09 箭头研究公司 Composition for targeted delivery siRNA
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
US20110256227A1 (en) 2010-04-14 2011-10-20 Intezyne Technologies, Inc. Controlled polyplex assembly
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
EP2395041A1 (en) 2010-06-10 2011-12-14 F. Hoffmann-La Roche AG Polymers for delivery of nucleic acids
WO2012005572A1 (en) 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
FR2963350B1 (en) 2010-07-30 2013-11-01 Univ D Evry Val D Essonne NOVEL BLOCK COPOLYMERS AND THEIR USES FOR DELIVERING AN ACTIVE SUBSTANCE INTO A CELL.
US8461224B2 (en) 2011-03-04 2013-06-11 National Health Research Institutes Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
US10029023B2 (en) 2011-03-31 2018-07-24 The Johns Hopkins University Theranostic imaging agents and methods of use
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
EP3272868A1 (en) 2012-05-02 2018-01-24 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat kras-related diseases
PL2852668T3 (en) 2012-07-12 2016-11-30 Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
JP2015536319A (en) 2012-10-16 2015-12-21 ウィリアム・マーシュ・ライス・ユニバーシティ Improved nanovector-based drug delivery system to overcome drug resistance
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
EP2919774A4 (en) 2012-11-15 2016-11-09 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
US9816095B2 (en) 2012-12-06 2017-11-14 Kyowa Hakko Bio Co., Ltd. Double-stranded ribonucleic acid for adjuvants
EA036400B1 (en) 2013-06-28 2020-11-06 Этрис Гмбх Compositions for introducing rna into cells
CN104341488A (en) 2013-08-02 2015-02-11 复旦大学 c(LyP-1) polypeptide and nano-delivery system constructed thereby and application of nano-delivery system
WO2015065773A1 (en) 2013-11-04 2015-05-07 Northeastern University System for co-delivery of polynucleotides and drugs into protease-expressing cells
US20160271268A1 (en) 2013-11-08 2016-09-22 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery
ES2834927T3 (en) 2014-03-14 2021-06-21 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of manufacture and use thereof
EP3126501A1 (en) 2014-03-24 2017-02-08 RiboxX GmbH Double-stranded rna conjugates and their use
JP7348708B2 (en) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Combination vaccine device and method for killing cancer cells
KR102472590B1 (en) * 2014-05-14 2022-11-30 타르그이뮨 테라퓨틱스 아게 Improved polyethyleneimine polyethyleneglycol vectors
AU2016214978B2 (en) 2015-02-05 2021-12-09 The University Of Queensland Targeting constructs for delivery of payloads
WO2016183447A1 (en) 2015-05-14 2016-11-17 The Johns Hopkins University Compositions of nucleic acid-containing nanoparticles for in vivo delivery
DE202016008594U1 (en) 2015-11-17 2018-08-23 Bioncotech Therapeutics S.L A novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Also Published As

Publication number Publication date
MX2016014881A (en) 2017-05-01
PH12016502258A1 (en) 2017-02-27
AU2021203336A1 (en) 2021-06-24
RU2016146389A (en) 2018-06-15
ZA201608042B (en) 2018-11-28
CA2949017A1 (en) 2015-11-19
NZ764423A (en) 2021-08-27
JP2020196739A (en) 2020-12-10
IL287206A (en) 2021-12-01
US20170072063A1 (en) 2017-03-16
IL287206B1 (en) 2023-10-01
KR102472590B1 (en) 2022-11-30
CN106687121A (en) 2017-05-17
EP3142673A1 (en) 2017-03-22
US10278991B2 (en) 2019-05-07
JP6753843B2 (en) 2020-09-16
CN116966311A (en) 2023-10-31
KR102589295B1 (en) 2023-10-13
NZ727092A (en) 2021-07-30
RU2771104C2 (en) 2022-04-26
US20220339189A1 (en) 2022-10-27
MX2020012698A (en) 2021-02-15
IL248890B (en) 2021-10-31
US10543232B2 (en) 2020-01-28
KR20220163536A (en) 2022-12-09
JP2017521090A (en) 2017-08-03
AU2015260725B2 (en) 2021-02-25
CN116966310A (en) 2023-10-31
US20190262395A1 (en) 2019-08-29
IL287206B2 (en) 2024-02-01
KR20170005052A (en) 2017-01-11
WO2015173824A1 (en) 2015-11-19
US11298376B2 (en) 2022-04-12
MA39970A (en) 2015-11-19
IL248890A0 (en) 2017-01-31
US20190192563A1 (en) 2019-06-27
AU2015260725A1 (en) 2016-12-22
SG10201911695SA (en) 2020-01-30
RU2016146389A3 (en) 2018-12-26
JP7406475B2 (en) 2023-12-27
BR112016026581A2 (en) 2017-10-31
JP2024028995A (en) 2024-03-05
EP3142673A4 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
IL287206A (en) Improved polyethyleneimine polyethyleneglycol vectors
GB201715843D0 (en) No details
GB2549809C (en) Vector
RS60586B1 (en) Lentiviral vectors
GB201403684D0 (en) Vector
GB201715887D0 (en) No details
GB201622033D0 (en) No details
GB201714253D0 (en) No details
GB201411344D0 (en) Cloning
GB201412494D0 (en) Vector production
GB201509578D0 (en) Vectors
GB201614093D0 (en) Vector
GB201702043D0 (en) No details
GB201709809D0 (en) No details
GB201703185D0 (en) No details
IL247535B (en) Poxviral oncolytic vectors
PL3237349T3 (en) Improved biobinder
GB201509881D0 (en) Complementary vectors
GB201419801D0 (en) Antennas
GB201402083D0 (en) Retaining means
GB201709361D0 (en) No details
GB201709806D0 (en) No details
GB201711661D0 (en) No details
GB201710661D0 (en) No details
GB201714201D0 (en) No details